Mk. Martel et al., DOSE-VOLUME HISTOGRAM AND 3-D TREATMENT PLANNING EVALUATION OF PATIENTS WITH PNEUMONITIS, International journal of radiation oncology, biology, physics, 28(3), 1994, pp. 575-581
Citations number
25
Categorie Soggetti
Oncology,"Radiology,Nuclear Medicine & Medical Imaging
Purpose: Tolerance of normal lung to inhomogeneous irradiation of part
ial volumes is not well understood. This retrospective study analyzes
three-dimensional (3-D) dose distributions and dose-volume histograms
for 63 patients who have had normal lung irradiated in two types of tr
eatment situations. Methods and Materials: 3-D treatment plans were ex
amined for 21 patients with Hodgkin's disease and 42 patients with non
small-cell lung cancer. All patients were treated with conventional fr
actionation, with a dose of 67 Gy (corrected) or higher for the lung c
ancer patients. A normal tissue complication probability description a
nd a dose-volume histogram reduction scheme were used to assess the da
ta. Mean dose to lung was also calculated. Results: Five Hodgkin's dis
ease patients and nine lung cancer patients developed pneumonitis. Dat
a were analyzed for each individual independent lung and for the total
lung tissue (lung as a paired organ). Comparisons of averages of mean
lung dose and normal tissue complication probabilities show a differe
nce between patients with and without complications. Averages of calcu
lated normal tissue complication probabilities for groups of patients
show that empirical model parameters correlate with actual complicatio
n rates for the Hodgkin's patients, but not as well for the individual
lungs of the lung cancer patients treated to larger volumes of normal
lung and high doses. Conclusion: This retrospective study of the 3-D
dose distributions for normal lung for two types of treatment situatio
ns for patients with irradiated normal lung gives useful data for the
characterization of the dose-volume relationship and the development o
f pneumonitis. These data can be used to help set up a dose escalation
protocol for the treatment of nonsmall-cell lung cancer.